Bradykinin (1-5)
Based on 1 Customer Validation
Bradykinin (1-5) is a metabolite of Bradykinin (HY-P0206) and a PAR inhibitor that inhibits thrombin-induced platelet aggregation by preventing protease-activated receptor (Protease Activated Receptor) cleavage and inhibiting Thrombin (MW 37kDa) (HY-114164). Bradykinin (1-5) is used in research on thrombosis, carrageenan-induced pleurisy, nasal allergy, and hereditary angioedema.
For research use only. We do not sell to patients.
- Purity : 99.46%
- CAS No.: 23815-89-6
- Formula: C27H40N8O6
- Molecular Weight:572.66
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P1469
Bradykinin (1-6)Bradykinin Receptor Modulator -
HY-P0206
BradykininBradykinin Receptor Modulator -
HY-P1490
Bradykinin (2-9)Peptide -
HY-P1484
Bradykinin (1-7)Bradykinin Receptor Modulator -
![[Des-Arg9]-Bradykinin acetate](https://file.medchemexpress.com/product_pic/hy-p0298a.gif)
HY-P0298A
[Des-Arg9]-Bradykinin acetateBradykinin Receptor Agonist -
HY-17446
IcatibantBradykinin Receptor Antagonist -
![[Hyp3]-Bradykinin](https://file.medchemexpress.com/product_pic/hy-p3061.gif)
HY-P3061
[Hyp3]-BradykininBradykinin Receptor Agonist -
HY-108896
Icatibant acetateBradykinin B2 Antagonist -
HY-15039
SSR240612 -
![[Des-Arg9]-Bradykinin](https://file.medchemexpress.com/product_pic/hy-p0298.gif)
HY-P0298
[Des-Arg9]-BradykininBradykinin (B1) Receptor Agonist -
HY-15043
ELN-441958Bradykinin B1 Receptor Antagonist -
HY-P4676
Lys-(Des-Arg9,Leu8)-BradykininBradykinin Receptor Antagonist
Biological Activity
Description
In Vitro
Bradykinin (1-5) (500 nM) significantly attenuates
Human α-Thrombin (HY-114164A)-induced platelet aggregation in human PRP, but the in vitro concentration required to inhibit Human γ-Thrombin (HY-114164B)-induced platelet aggregation reaches 7 mM, indicating a markedly lower ex vivo potency[1].
Bradykinin (1-5) (265.5-17700.0 pmol/L; 4-24 h) allows quantification of BK1-5 in human whole blood, with an LLOQ of 265.5 pmol/L and an LOD of 35.4 pmol/L[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
BK-(1-5) is the major and most stable kinin metabolite in carrageenan-induced pleurisy in rats, reaching a peak of 8800 pg/rat at 3 h and closely correlating with plasma exudation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Healthy nonsmoking subjects (22 men and 14 women; 29 white, 7 black; mean age 29.8 years; mean BMI 26.0 kg/m2)[1]
-
Dosage:47, 94, 188, and 377 pmol/min (first ten subjects); 377, 754, 3770, and 18,850 pmol/min (next 15 subjects); 37, 188, 377, and 754 pmol/min (dose-platelet inhibition-response experiments)
-
Administration:intra-arterial; each dose infused for 5 min
-
Result:Did not affect forearm blood flow at doses up to 18,850 pmol/min.
Had no effect on net t-PA release at doses up to 18,850 pmol/min.
Had no effect on net PAI-1 extraction at doses up to 18,850 pmol/min.
Increased venous concentration dose-dependently from 48.9 to 2099.5 fmol/mL (equimolar doses 47-377 pmol/min) and from 44.7 to 79,359 fmol/mL (up to 18,850 pmol/min).
Significantly attenuated α-thrombin-induced platelet aggregation (16% aggregation during infusion vs 88% at baseline).
Had no effect on TRAP 1-6-induced platelet aggregation (56.13% during infusion vs 52.2% at baseline).
Inhibited γ-thrombin (500 nM)-induced platelet aggregation with an ED50 of 183 pmol/min.
Chemical Information
-
CAS No. 23815-89-6
-
Appearance Solid
-
Molecular Weight 572.66
-
Formula C27H40N8O6
-
Color White to off-white
-
Sequence
Arg-Pro-Pro-Gly-Phe
-
Sequence Shortening
RPPGF
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (174.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7462 mL | 8.7312 mL | 17.4624 mL | 43.6559 mL |
| 5 mM | 0.3492 mL | 1.7462 mL | 3.4925 mL | 8.7312 mL | |
| 10 mM | 0.1746 mL | 0.8731 mL | 1.7462 mL | 4.3656 mL | |
| 15 mM | 0.1164 mL | 0.5821 mL | 1.1642 mL | 2.9104 mL | |
| 20 mM | 0.0873 mL | 0.4366 mL | 0.8731 mL | 2.1828 mL | |
| 25 mM | 0.0698 mL | 0.3492 mL | 0.6985 mL | 1.7462 mL | |
| 30 mM | 0.0582 mL | 0.2910 mL | 0.5821 mL | 1.4552 mL | |
| 40 mM | 0.0437 mL | 0.2183 mL | 0.4366 mL | 1.0914 mL | |
| 50 mM | 0.0349 mL | 0.1746 mL | 0.3492 mL | 0.8731 mL | |
| 60 mM | 0.0291 mL | 0.1455 mL | 0.2910 mL | 0.7276 mL | |
| 80 mM | 0.0218 mL | 0.1091 mL | 0.2183 mL | 0.5457 mL | |
| 100 mM | 0.0175 mL | 0.0873 mL | 0.1746 mL | 0.4366 mL |
Bradykinin (1-5) Related Classifications
HY-P1488 Related Classifications
Powered by Bioz